Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Oncolytic virotherapy using coxsackie virus

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 1783

Dr Hardev Pandha - University of Surrey, Guildford, UK

Dr Pandha speaks with ecancertv at ESMO 2016 about two trials of coxsackie virus as an immune modulator.

Oncolytic virotherapy is discussed more broadly in an ecancer review here.

Dr Pandha describes results from the CANON trial of virotherapy for bladder cancer, and the STORM / KEYNOTE200 trial which combined virotherapy with immune modulator pembrolizumab.

He describes how viral stimulation of immune activity, further enhanced by checkpoint inhibitors, can have significant outcomes, and considers wider adoption of virotherapy to complement other treatment modalities.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation